Pharmaceutical Competitive Intelligence & Market Intelligence Reports Larvol

LARVOL Pulse ™

Market Intelligence

STAY AHEAD OF YOUR COMPETITORS

LARVOL PULSE™ MARKET INTELLIGENCE REPORTS

Monitor Your Competitors. Collect, prioritize and track information on compounds competitive to your internal pipeline. Take the lead with comprehensive pharmaceutical intelligence delivered to you in real-time.

WHY SUBSCRIBE TO PULSE™?

Dominate the Marketplace. In order to thrive in the pharmaceutical industry, it’s essential to stay abreast of new developments that may have a direct impact on your business. Our market intelligence reports help you to be at the forefront of the rapidly changing competitive landscape with insights on clinical trials, conference coverage, product milestones and news releases.

Filtered News Items. Our team of experts filter thousands of signals into news items that would be of interest to you based on novelty, relevance and impact. High impact news (based on analysis and customer feedback) is delivered directly to your email as a real-time alert.

HOW DOES IT WORK?

Complete Coverage. We cover over 25,000 general news sources, ranging from PubMed, CT.gov/EudraCT, FDA/EMA, social media and over 900 scientific congresses. We also include any healthcare investor conferences, corporate communications, earning calls and financial news.

Automatic Reports + Searchable Online Portal. You receive weekly summary reports and real-time alerts detailing developments on the assets you’ve chosen. Plus you get access to an online portal to search and track past updates.

RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

[NEW] 02/05/2018, Actemra IV / Roche

Not yet recruiting; Sponsor: Mario Negri Institute for Pharmacological Research; Initiation date: Nov 2017 --> Feb 2018

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants WIth Early, Moderate to Severe Rheumatoid Arthritis

[NEW] 02/05/2018, Actemra IV / Roche

Terminated; Sponsor: Hoffmann-I. a Roche; Completed --> Terminated; Study was terminated by sponsor due to market authoriation of tocilizumab for the study population.

Quebec adds Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases

[NEW] 02/05/2018, Erelzi / Novartis

Quebec is the most recent province to have added Erelzi™ (etanercept) 50 mg to its formulary of exception drugs covered by the province's Public Precription Drug Insurance Plan for the treatment of multiple inflammatory diseases.

PULSE™ FILTERED NEWS TRACKING INCLUDES:

News Alerts

• Real-time high-impact news delivered directly to your inbox

• Weekly summary reports filtered on impact rating

Heatmaps

• Customized for premium products

• Visualize trial activity according to specific conditions, MOAs, biomarkers, etc.

Online Portal

• Filter clinical trials based on region, product, size, phase, etc.

• Quarterly product pipeline updates

• Key product milestones and associated timeframes

Sources

• 25k+ news sources including PubMed and CT.gov

• 900+ scientific congresses

• Social media

FEATURED ANALYTICS:

News Highlights
Quickly review top, weekly developments in a given market
Competitor Heatmaps
Track the intensity of activity by MOA, drug class, and more
Dashboards
See competitor developments in a glance
Key Clinical Trials
Monitor timeline or parameter changes for competitor trials
Anticipated Events
Browse a timeline with upcoming conferences, webcasts and more
Product News
Review detailed news for each product in your area of interest
Blog Postings
See what patients and doctors are saying about various products
Product Milestones
Stay abreast of important product developments
Expected Launch Dates
Track anticipated launch timelines

TRACKING SERVICES:

Brand-Level Tracking
Track a specific brand and its unique set of competitors; related clinical, regulatory and commercial developments; and more.
Franchise-Level Tracking
Track everything from broad therapeutic area monitoring (e.g. diabetes, oncology) to specific Mechanisms of Action (MOAs) or tumor types.
Biomarker & Other Scientific Tracking
Focus on biomarker developments within a specific area (e.g. oncology). It is also possible to track patent activity or other scientific parameters.
Strategic Tracking
Track any issues of strategic interest. Examples of ongoing initiatives include emerging markets (R&D, commercial, expressed strategic intent, investments, partnerships etc), biosimilar development, and more.
Clinical Trial Tracking
Our trial database merges data from clinicaltrials.gov and EudraCT into a single, user-friendly platform that includes advanced visualization applications.